Charles River Laboratories International, Inc. (NYSE:CRL) Short Interest Update

Charles River Laboratories International, Inc. (NYSE:CRL) was the target of a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 2,000,000 shares, a drop of 7.4% from the January 15th total of 2,160,000 shares. Based on an average trading volume of 785,400 shares, the days-to-cover ratio is currently 2.5 days.

Institutional Trading of Charles River Laboratories International

A number of institutional investors have recently added to or reduced their stakes in CRL. Vanguard Group Inc. raised its holdings in shares of Charles River Laboratories International by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company’s stock valued at $1,136,938,000 after purchasing an additional 60,497 shares in the last quarter. Wellington Management Group LLP increased its position in Charles River Laboratories International by 9.0% during the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company’s stock worth $752,508,000 after buying an additional 335,658 shares during the last quarter. State Street Corp raised its holdings in Charles River Laboratories International by 2.0% during the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after buying an additional 41,421 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Charles River Laboratories International by 2.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock worth $330,231,000 after buying an additional 47,221 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Charles River Laboratories International by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company’s stock worth $227,042,000 after acquiring an additional 14,787 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently commented on CRL shares. CLSA downgraded Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective on the stock. in a research note on Monday, November 18th. Bank of America dropped their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Evercore ISI raised their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a report on Thursday, November 7th. StockNews.com lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. Finally, JPMorgan Chase & Co. reduced their target price on Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a report on Monday, February 3rd. Three investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $200.79.

Charles River Laboratories International Stock Down 0.7 %

Shares of Charles River Laboratories International stock traded down $1.10 during trading on Monday, hitting $152.07. 841,129 shares of the stock traded hands, compared to its average volume of 1,002,698. The stock has a market cap of $7.78 billion, a P/E ratio of 19.03, a PEG ratio of 6.47 and a beta of 1.37. The company has a fifty day moving average price of $175.44 and a two-hundred day moving average price of $189.72. Charles River Laboratories International has a twelve month low of $150.79 and a twelve month high of $275.00. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).